Corvus Pharmaceuticals (CRVS) said late Wednesday preclinical data highlighting the potential of soquelitinib as a novel approach to modulate tumor immunity was published in npj Drug Discovery, a peer-reviewed journal.

The publication includes an overview of soquelitinib's mechanism of action, suppressing the production of Th2 and Th17 cytokine while sparing Th1 cytokines. The company said this is a novel approach to cancer immunotherapy.

"The data also shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and leads to an increase in memory T cells with enhanced effector function," the company said.